首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer biology & medicine

缩写:

ISSN:2095-3941

e-ISSN:2095-3941

IF/分区:12.4/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引1065
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Yueying Zhang,Shanrui Ma,Xinqing Li et al. Yueying Zhang et al.
Objective: Upper gastrointestinal (UGI) cancer, including esophageal and gastric cancers, poses a significant health burden. While unhealthy dietary patterns are a recognized risk factor for UGI cancer, the complex interp...
Yinghong Lu,Jun Yu Yinghong Lu
Colorectal cancer (CRC) remains a major global health burden with the gut microbiome emerging as a critical contributor to tumor initiation and progression. Advances in high-throughput sequencing have deepened our understanding of host-micr...
Sihan Li,Fashun Li,Jiasheng Tu et al. Sihan Li et al.
Postbiotics, considered the functional successors of live probiotics, retain most of probiotics' structural and/or bioactive properties, and are key mediators of probiotic-environment interactions. Beyond influencing tumor proliferation, me...
Yang Zhang,Wangyang Zhu,Chaoqiang Deng et al. Yang Zhang et al.
Objective: Progressive metabolic adaptation of tumor cells enables a thriving tumor microenvironment in which immune cells have diminished killing ability. However, whether and how this adaptation plays an active role in ...
Zhenying Guo,Chunwei Xu,Shirong Zhang et al. Zhenying Guo et al.
As an emerging biomarker, tumor mutational burden (TMB) has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy. Currently, TMB is detected primarily by whole-exome sequencing or targeted panel s...
Xuhong Chen,Dongxian Tan,Shuaiting Liu et al. Xuhong Chen et al.
In the past decade, cancer immunotherapy has emerged as a transformative treatment modality for diverse malignancies. Although impressive clinical efficacy has been demonstrated in some cancer patients, most patients respond poorly to immun...
Yanna Bi,Sisi Wei,Zhe Zhang et al. Yanna Bi et al.
Objective: Paclitaxel (PTX), a conventional second-line therapeutic agent for advanced gastric cancer (GC), exhibits compromised clinical efficacy due to acquired chemoresistance in patients, the molecular mechanisms of w...
Zhengyang Bai,Dan Yang,Jiayi Li et al. Zhengyang Bai et al.
Objective: Breast cancer is the most common malignancy in women and is characterized by a high recurrence rate that severely impacts patient survival. Regulatory T cells (Tregs) in the tumor microenvironment (TME) promote...
Zijian Lv,Tiance Wang,Runjia Fan et al. Zijian Lv et al.
Objective: Clinical use of stimulator of interferon genes (STING) agonists has challenges due to poor responsiveness and variable efficacy. Therefore, identifying tumor types that are sensitive to these agents and clarify...
Yangyang Zhang,Jingli Xu,Siwei Pan et al. Yangyang Zhang et al.
In recent years the crucial role of CD4+ T cells in tumor immunomodulation has garnered increasing recognition. While conventional cancer immunotherapy research has predominantly focused on the cytotoxic function of CD8+ T cells, emerging e...